Abstract
Whilst various remedial human monoclonal antibodies have been developed to treat the potentiallylife-threatening systemic complications associated with anthrax infection, an optimal and universally effective administration route has yet to be established. In the later stages of infection when antibody administration by injection is more likely to fail one possible route to improve outcome is via theuse of an antibody-bound, adsorbent haemoperfusion device. We report here the development of an adsorbent macroporous polymer column containing immobilised B. anthracis exotoxin-specific antibodies, PANG (a non-glycosylated, version of a plant-produced human monoclonal antibody) and Valortim (a fully human monoclonal N-linked glycosylated antibody), for removal of anthrax protective antigen (PA) from freshly frozen human plasma and human whole blood. In addition, we have demonstrated that continuous extracorporeal blood recirculation through a Valortim-bound haemoperfusion column significantly reduced the blood plasma concentration of anthrax PA over 2hours using an in vivo PA rat infusion model. This work provides proof-of-concept evidence to supportthe development of such alternative detoxification platforms.
Original language | English |
---|---|
Article number | 7518 |
Pages (from-to) | 1-11 |
Number of pages | 11 |
Journal | Scientific Reports |
Volume | 8 |
DOIs | |
Publication status | Published - 14 May 2018 |